Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ischemic Heart Disease

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 196 articles:
HTML format



Single Articles


    March 2021
  1. ERLINGE D, Maehara A, Ben-Yehuda O, Botker HE, et al
    Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study.
    Lancet. 2021;397:985-995.
    PubMed     Abstract available


    February 2021
  2. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    PubMed     Abstract available


    January 2021
  3. KAURA A, Sterne JAC, Trickey A, Mayet J, et al
    Managing NSTEMI in older patients - Authors' reply.
    Lancet. 2021;397:371-372.
    PubMed    


  4. CORDERO A, Rodriguez-Manero M, Bertomeu-Gonzalez V, Gonzalez-Juanatey JR, et al
    Managing NSTEMI in older patients.
    Lancet. 2021;397:370-371.
    PubMed    


  5. VERSACI F, Frati G, Biondi-Zoccai G
    Managing NSTEMI in older patients.
    Lancet. 2021;397:370.
    PubMed    


  6. D'ASCENZO F, De Filippo O, Gallone G, Mittone G, et al
    Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets.
    Lancet. 2021;397:199-207.
    PubMed     Abstract available


  7. TEMPLIN C, Di Vece D
    Risk scores in predicting adverse events following acute coronary syndrome.
    Lancet. 2021;397:172-173.
    PubMed    


    December 2020
  8. JACKSON R, Wells S, Rodgers A
    Cardiovascular preventive strategies are not conflicting.
    Lancet. 2020;396:1879-1880.
    PubMed    


    November 2020
  9. RAAL FJ, Mohamed F
    Never too old to benefit from lipid-lowering treatment.
    Lancet. 2020;396:1608-1609.
    PubMed    


  10. GENCER B, Marston NA, Im K, Cannon CP, et al
    Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
    Lancet. 2020;396:1637-1643.
    PubMed     Abstract available


  11. SILVAIN J, Lattuca B, Beygui F, Range G, et al
    Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32236.
    PubMed     Abstract available


  12. MORTENSEN MB, Nordestgaard BG
    Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort.
    Lancet. 2020 Nov 9. pii: S0140-6736(20)32233.
    PubMed     Abstract available


  13. MACKENZIE IS, Ford I, Nuki G, Hallas J, et al
    Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2020 Nov 6. pii: S0140-6736(20)32234.
    PubMed     Abstract available


    October 2020
  14. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.
    Lancet. 2020 Oct 19. pii: S0140-6736(20)32173.
    PubMed     Abstract available


  15. TAKAHASHI K, Serruys PW, Fuster V, Farkouh ME, et al
    Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNT
    Lancet. 2020 Oct 8. pii: S0140-6736(20)32114.
    PubMed     Abstract available


  16. RAMCHAND J, Burrell LM
    Circulating ACE2: a novel biomarker of cardiovascular risk.
    Lancet. 2020;396:937-939.
    PubMed    


    September 2020

  17. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4.
    Lancet. 2020;396:918-934.
    PubMed     Abstract available


    August 2020
  18. KAURA A, Sterne JAC, Trickey A, Abbott S, et al
    Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data.
    Lancet. 2020;396:623-634.
    PubMed     Abstract available


  19. BENDZ B, Aaberge L
    Acute coronary syndromes in older patients: does older age matter?
    Lancet. 2020;396:585-587.
    PubMed    


  20. FERRARI R, Ford I, Fox K, Challeton JP, et al
    Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31790.
    PubMed     Abstract available


  21. KIM HS, Kang J, Hwang D, Han JK, et al
    Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31791.
    PubMed     Abstract available


  22. MACLAREN G
    In sepsis-induced heart failure, extracorporeal membrane oxygenation can provide support.
    Lancet. 2020;396:515-517.
    PubMed    


  23. BRECHOT N, Hajage D, Kimmoun A, Demiselle J, et al
    Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study.
    Lancet. 2020;396:545-552.
    PubMed     Abstract available


  24. SCHWALM JD, McCready T, Islam S, McKee M, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4 - Authors' reply.
    Lancet. 2020;396:310-311.
    PubMed    


  25. RICHARDS A
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:310.
    PubMed    


  26. HENDRIKS M, van Andel J, Asiki G, Kyobutungi C, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:309-310.
    PubMed    


    July 2020
  27. COMBES A, Price S, Slutsky AS, Brodie D, et al
    Temporary circulatory support for cardiogenic shock.
    Lancet. 2020;396:199-212.
    PubMed     Abstract available


  28. MAFHAM MM, Spata E, Goldacre R, Gair D, et al
    COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England.
    Lancet. 2020 Jul 14. pii: S0140-6736(20)31356.
    PubMed     Abstract available


  29. CHI G, Marszalek J
    Differential effect of ticagrelor on irreversible harms in diabetes.
    Lancet. 2020;396:93.
    PubMed    


    June 2020
  30. STRONGMAN H, Lyon AR, Dos Santos Silva I, Smeeth L, et al
    Cancer and cardiovascular disease - Authors' reply.
    Lancet. 2020;395:1904-1905.
    PubMed    


  31. KNISELY JPS, Henry SA, Saba SG, Puckett LL, et al
    Cancer and cardiovascular disease.
    Lancet. 2020;395:1904.
    PubMed    


  32. ALAM N, Wright AK, Ashcroft DM, Renehan AG, et al
    Cancer and cardiovascular disease.
    Lancet. 2020;395:1903-1904.
    PubMed    



  33. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
    Lancet. 2020;395:1927-1936.
    PubMed     Abstract available


    May 2020
  34. BUGIARDINI R, Cenko E
    Sex differences in myocardial infarction deaths.
    Lancet. 2020 May 20. pii: S0140-6736(20)31049.
    PubMed    


  35. WALLI-ATTAEI M, Joseph P, Rosengren A, Chow CK, et al
    Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
    Lancet. 2020 May 20. pii: S0140-6736(20)30543.
    PubMed     Abstract available


  36. HOLMES JL, Brake S, Docherty M, Lilford R, et al
    Emergency ambulance services for heart attack and stroke during UK's COVID-19 lockdown.
    Lancet. 2020 May 14. pii: S0140-6736(20)31031.
    PubMed    


  37. BYRNE RA, Colleran R
    Aspirin for secondary prevention of cardiovascular disease.
    Lancet. 2020;395:1462-1463.
    PubMed    


  38. CHIARITO M, Sanz-Sanchez J, Cannata F, Cao D, et al
    Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.
    Lancet. 2020;395:1487-1495.
    PubMed     Abstract available


    April 2020
  39. GIMBEL M, Qaderdan K, Willemsen L, Hermanides R, et al
    Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Lancet. 2020;395:1374-1381.
    PubMed     Abstract available


  40. SINNAEVE PR, Gevaert SA
    Antiplatelet strategies in ageing patients with acute coronary syndromes.
    Lancet. 2020;395:1319-1321.
    PubMed    


    March 2020
  41. HERRETT E, Jackson R, Smeeth L
    Managing cardiovascular disease risk in hypertension - Authors' reply.
    Lancet. 2020;395:870.
    PubMed    


  42. MCMANUS R, Constanti M, Floyd CN, Glover M, et al
    Managing cardiovascular disease risk in hypertension.
    Lancet. 2020;395:869-870.
    PubMed    


    February 2020

  43. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.
    Lancet. 2020;395:698-708.
    PubMed     Abstract available


  44. DASA O, Ruzieh M
    Polypill for prevention of cardiovascular diseases.
    Lancet. 2020;395:414.
    PubMed    


  45. ROSHANDEL G, Kamangar F, Marshall T, Cheng KK, et al
    Polypill for prevention of cardiovascular diseases - Authors' reply.
    Lancet. 2020;395:414-415.
    PubMed    


  46. DIMMITT SB, Stampfer HG
    Polypill for prevention of cardiovascular diseases.
    Lancet. 2020;395:413-414.
    PubMed    


    January 2020
  47. MORICE MC
    Patients with left main coronary artery disease: stent or surgery?
    Lancet. 2020;395:167-168.
    PubMed    


    December 2019
  48. HOLM NR, Makikallio T, Lindsay MM, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.
    Lancet. 2019 Dec 23. pii: S0140-6736(19)32972.
    PubMed     Abstract available


  49. BRUNNER FJ, Waldeyer C, Ojeda F, Salomaa V, et al
    Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium.
    Lancet. 2019 Dec 3. pii: S0140-6736(19)32519.
    PubMed     Abstract available


  50. ROBINSON JG
    The next treatment paradigm in cardiovascular prevention?
    Lancet. 2019 Dec 3. pii: S0140-6736(19)32949.
    PubMed    


    October 2019
  51. SUCHARD MA, Schuemie MJ, Krumholz HM, You SC, et al
    Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
    Lancet. 2019 Oct 24. pii: S0140-6736(19)32317.
    PubMed     Abstract available


  52. VANEZIS AP
    The broken promise of remote ischaemic conditioning.
    Lancet. 2019;394:1389-1390.
    PubMed    


  53. VON BIRGELEN C, Buiten RA
    Superiority of biodegradable polymer sirolimus-eluting stents in STEMI.
    Lancet. 2019;394:1208-1210.
    PubMed    


    September 2019
  54. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    PubMed     Abstract available


  55. ERLINGE D
    NIRS-intravascular imaging to predict coronary events.
    Lancet. 2019 Sep 26. pii: S0140-6736(19)32217.
    PubMed    


  56. WAKSMAN R, Di Mario C, Torguson R, Ali ZA, et al
    Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study.
    Lancet. 2019 Sep 26. pii: S0140-6736(19)31794.
    PubMed     Abstract available


  57. HAUSENLOY DJ, Kharbanda RK, Moller UK, Ramlall M, et al
    Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
    Lancet. 2019 Sep 6. pii: S0140-6736(19)32039.
    PubMed     Abstract available


  58. READ SH, Wild SH
    Prevention of premature cardiovascular death worldwide.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)32034.
    PubMed    


  59. VRANCKX P, Valgimigli M, Eckardt L, Tijssen J, et al
    Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)31872.
    PubMed     Abstract available


  60. YUSUF S, Joseph P, Rangarajan S, Islam S, et al
    Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)32008.
    PubMed     Abstract available


    August 2019
  61. IGLESIAS JF, Muller O, Heg D, Roffi M, et al
    Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31877.
    PubMed     Abstract available


  62. THUIJS DJFM, Kappetein AP, Serruys PW, Mohr FW, et al
    Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31997.
    PubMed     Abstract available


  63. TAGGART DP, Pagano D
    Expansion or contraction of stenting in coronary artery disease?
    Lancet. 2019 Aug 30. pii: S0140-6736(19)32040.
    PubMed    


  64. SCHWALM JD, McCready T, Lopez-Jaramillo P, Yusoff K, et al
    A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31949.
    PubMed     Abstract available


  65. JAFAR TH, Samad Z, Bloomfield GS
    Parallel community solutions for cardiovascular risk reduction.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31995.
    PubMed    


  66. BHATT DL, Steg PG, Mehta SR, Leiter LA, et al
    Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31887.
    PubMed     Abstract available


  67. VALGIMIGLI M, Manavifar N
    Ticagrelor in patients with diabetes and previous PCI.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31957.
    PubMed    


  68. STAFF AC
    Long-term cardiovascular health after stopping pre-eclampsia.
    Lancet. 2019 Aug 28. pii: S0140-6736(19)31993.
    PubMed    


  69. NASLUND U, Ng N, Wennberg P, Norberg M, et al
    Patient-doctor engagement in cardiovascular prevention - Authors' reply.
    Lancet. 2019;394:e27.
    PubMed    


  70. ANYFANTI P, Gkaliagkousi E, Douma S
    Patient-doctor engagement in cardiovascular prevention.
    Lancet. 2019;394:e26.
    PubMed    


  71. RAY KK, Corral P, Morales E, Nicholls SJ, et al
    Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options.
    Lancet. 2019;394:697-708.
    PubMed     Abstract available


  72. GUPTA R, Wood DA
    Primary prevention of ischaemic heart disease: populations, individuals, and health professionals.
    Lancet. 2019;394:685-696.
    PubMed     Abstract available


  73. ROSHANDEL G, Khoshnia M, Poustchi H, Hemming K, et al
    Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet. 2019;394:672-683.
    PubMed     Abstract available


  74. STRONGMAN H, Gadd S, Matthews A, Mansfield KE, et al
    Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.
    Lancet. 2019 Aug 20. pii: S0140-6736(19)31674.
    PubMed     Abstract available


  75. BLAES AH, Shenoy C
    Is it time to include cancer in cardiovascular risk prediction tools?
    Lancet. 2019 Aug 20. pii: S0140-6736(19)31886.
    PubMed    


  76. NASLUND U, Lundgren A, Vanoli D, Norberg M, et al
    Is intima-media thickness a predictor for cardiovascular risk? - Authors' reply.
    Lancet. 2019;394:381.
    PubMed    


  77. GONZALEZ-CANTERO A, Gonzalez-Cantero J, Sanchez-Moya AI, Rodriguez-Padial L, et al
    Is intima-media thickness a predictor for cardiovascular risk?
    Lancet. 2019;394:380-381.
    PubMed    


    July 2019
  78. HERRETT E, Gadd S, Jackson R, Bhaskaran K, et al
    Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
    Lancet. 2019 Jul 25. pii: S0140-6736(19)31359.
    PubMed     Abstract available


    June 2019
  79. BARNETT R
    Acute myocardial infarction.
    Lancet. 2019;393:2580.
    PubMed    


  80. TIJSSEN RYG, de Winter RJ, Wykrzykowska JJ
    ABSORB IV: will the low rate of scaffold thrombosis persist?
    Lancet. 2019;393:2392.
    PubMed    


  81. STONE GW, Ellis SG, Kereiakes DJ
    ABSORB IV: will the low rate of scaffold thrombosis persist? - Authors' reply.
    Lancet. 2019;393:2392-2393.
    PubMed    


  82. RISSANEN TT, Uskela S, Eranen J, Mantyla P, et al
    Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.
    Lancet. 2019 Jun 13. pii: S0140-6736(19)31126.
    PubMed     Abstract available


  83. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    PubMed     Abstract available


  84. OIKONOMOU EK, Antoniades C
    Detection of coronary inflammation - Authors' reply.
    Lancet. 2019;393:2199-2200.
    PubMed    


    May 2019
  85. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    PubMed     Abstract available


  86. FUDIM M, Ali-Ahmed F, Patel MR, Sobotka PA, et al
    Sham trials: benefits and risks for cardiovascular research and patients.
    Lancet. 2019;393:2104-2106.
    PubMed    


  87. JEGER RV, Kaiser C, Gilgen N, Coslovsky M, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2 - Authors' reply.
    Lancet. 2019;393:1934-1935.
    PubMed    


  88. SAJADIEH A, Kumarathurai P, Jeppesen JL
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1934.
    PubMed    


  89. ALFONSO F, Guimaraes MG, Rivero F, Cuesta J, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1933-1934.
    PubMed    


  90. SHAH R, Khan B
    The MATRIX trial.
    Lancet. 2019;393:1803.
    PubMed    


  91. MEYER TM, Hollenbeck M, Kielstein JT
    The MATRIX trial.
    Lancet. 2019;393:1802-1803.
    PubMed    


  92. PICCOLO R, Bonaa KH, Efthimiou O, Varenne O, et al
    Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.
    Lancet. 2019 May 2. pii: S0140-6736(19)30474.
    PubMed     Abstract available


  93. JENSEN LO, Christiansen EH
    Are drug-eluting stents safer than bare-metal stents?
    Lancet. 2019 May 2. pii: S0140-6736(19)31000.
    PubMed    


    April 2019
  94. MCCALL B
    Alemtuzumab to be restricted pending review, says EMA.
    Lancet. 2019;393:1683.
    PubMed    


  95. MILLWOOD IY, Walters RG, Mei XW, Guo Y, et al
    Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)31772.
    PubMed     Abstract available


    March 2019
  96. THE LANCET EDITORS
    Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.
    Lancet. 2019;393:1084.
    PubMed    


  97. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed    


  98. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed    


  99. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed    


  100. BAX JJ, Di Carli M, Narula J, Delgado V, et al
    Multimodality imaging in ischaemic heart failure.
    Lancet. 2019;393:1056-1070.
    PubMed     Abstract available


  101. MCCRINDLE BW, Rowley AH
    Improving coronary artery outcomes for children with Kawasaki disease.
    Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.
    PubMed    


  102. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
    Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
    Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
    PubMed     Abstract available


    February 2019
  103. KIMURA T
    Can ultra-thin strut drug-eluting stents improve outcomes?
    Lancet. 2019 Feb 28. pii: S0140-6736(19)30286.
    PubMed    


  104. ZAMAN A, de Winter RJ, Kogame N, Chang CC, et al
    Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
    Lancet. 2019 Feb 28. pii: S0140-6736(18)32467.
    PubMed     Abstract available


  105. MEHRAN R, Vogel B, Ortega R, Cooney R, et al
    The Lancet Commission on women and cardiovascular disease: time for a shift in women's health.
    Lancet. 2019 Feb 8. pii: S0140-6736(19)30315.
    PubMed    


    December 2018
  106. NASLUND U, Ng N, Lundgren A, Fharm E, et al
    Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.
    Lancet. 2018 Dec 3. pii: S0140-6736(18)32818.
    PubMed     Abstract available


    November 2018
  107. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    PubMed     Abstract available


    October 2018
  108. COLOMBO A, Giannini F
    Encouraging data from ABSORB IV pave the way to new scaffolds.
    Lancet. 2018;392:1490-1491.
    PubMed    


  109. STONE GW, Ellis SG, Gori T, Metzger DC, et al
    Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
    Lancet. 2018;392:1530-1540.
    PubMed     Abstract available


  110. WILLEIT P, Ridker PM, Nestel PJ, Simes J, et al
    Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
    Lancet. 2018 Oct 4. pii: S0140-6736(18)31652.
    PubMed     Abstract available


  111. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    PubMed    


  112. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    PubMed     Abstract available


    September 2018
  113. CAMENZIND E, Popovic B
    Are all drug-eluting stents created equal?
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32334.
    PubMed    


  114. VON BIRGELEN C, Zocca P, Buiten RA, Jessurun GAJ, et al
    Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, ran
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32001.
    PubMed     Abstract available


  115. DEHGHAN M, Mente A, Rangarajan S, Sheridan P, et al
    Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2018 Sep 11. pii: S0140-6736(18)31812.
    PubMed     Abstract available


  116. HO HH, Ong PJL
    BASKET-SMALL 2: advancing DCB beyond in-stent restenosis.
    Lancet. 2018;392:802-804.
    PubMed    


  117. LANSKY A, Wijns W, Xu B, Kelbaek H, et al
    Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
    Lancet. 2018 Sep 3. pii: S0140-6736(18)31649.
    PubMed     Abstract available


  118. PILGRIM T, Piccolo R, Heg D, Roffi M, et al
    Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Lancet. 2018;392:737-746.
    PubMed     Abstract available


    August 2018
  119. VRANCKX P, Valgimigli M, Juni P, Hamm C, et al
    Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, ope
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31858.
    PubMed     Abstract available


  120. CAPODANNO D, Angiolillo DJ
    Aspirin for primary prevention of cardiovascular disease.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31990.
    PubMed    


  121. GAZIANO JM, Brotons C, Coppolecchia R, Cricelli C, et al
    Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31924.
    PubMed     Abstract available


  122. VALGIMIGLI M, Frigoli E, Leonardi S, Vranckx P, et al
    Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31714.
    PubMed     Abstract available


  123. ANGIOLILLO DJ
    Vascular access and antithrombotic therapy in patients with acute coronary syndrome.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31921.
    PubMed    


  124. BLANKENBERG S, Neumann JT, Westermann D
    Diagnosing myocardial infarction: a highly sensitive issue.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31996.
    PubMed    


  125. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31719.
    PubMed     Abstract available


  126. SHAH ASV, Anand A, Strachan FE, Ferry AV, et al
    High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31923.
    PubMed     Abstract available


  127. OIKONOMOU EK, Marwan M, Desai MY, Mancio J, et al
    Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31114.
    PubMed     Abstract available


  128. MAHABADI AA, Rassaf T
    Imaging of coronary inflammation for cardiovascular risk prediction.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31716.
    PubMed    


  129. MENTE A, O'Donnell M, Rangarajan S, McQueen M, et al
    Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.
    Lancet. 2018;392:496-506.
    PubMed     Abstract available


  130. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Abstract available


    July 2018
  131. THEKEN KN, Grosser T
    Weight-adjusted aspirin for cardiovascular prevention.
    Lancet. 2018 Jul 12. pii: S0140-6736(18)31307.
    PubMed    


  132. DOWLING C, Firoozi S, Brecker S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    PubMed    


  133. FRANCIS DP, Al-Lamee R
    Percutaneous coronary intervention for stable angina in ORBITA - Authors' reply.
    Lancet. 2018;392:28-30.
    PubMed    


  134. BANNING A, Redwood S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:28.
    PubMed    


  135. BAUER A, Rizas KD, Massberg S
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27.
    PubMed    


  136. REED GW, Kapadia SR
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:27-28.
    PubMed    


  137. POCOCK SJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26-27.
    PubMed    


  138. BARAKAT MF, Simitsis P
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:26.
    PubMed    


  139. TU T, Liu Q, Hu X, Zhou S, et al
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    PubMed    


  140. MUTHALALY RG, Nerlekar N, Brown AJ
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25-26.
    PubMed    


  141. DEGRELL P, Picard F, Varenne O
    Percutaneous coronary intervention for stable angina in ORBITA.
    Lancet. 2018;392:25.
    PubMed    


    June 2018
  142. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed    


  143. MARIATHAS M, Curzen N
    Troponin assays: developing indications.
    Lancet. 2018;391:2398-2399.
    PubMed    


  144. DEVEREAUX PJ, Duceppe E, Guyatt G, Tandon V, et al
    Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
    Lancet. 2018;391:2325-2334.
    PubMed     Abstract available


  145. IKEMURA N, Sawano M, Ueda I, Fukuda K, et al
    Consequence of reimbursement policy alteration for urgent PCI in Japan.
    Lancet. 2018;391:2208-2209.
    PubMed    


    May 2018
  146. MONTAIGNE D, Coisne A, Marechal X, Lefebvre P, et al
    Daytime variations in perioperative myocardial injury - Authors' reply.
    Lancet. 2018;391:2106.
    PubMed    


  147. SPADACCIO C, Dalby M, Danton MHD
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2105-2106.
    PubMed    


  148. LUCCHINETTI E, Zaugg M
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104-2105.
    PubMed    


  149. BARTMAN CM, Oyama Y, Eckle T
    Daytime variations in perioperative myocardial injury.
    Lancet. 2018;391:2104.
    PubMed    


  150. BRILAKIS ES, Edson R, Bhatt DL, Goldman S, et al
    Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
    Lancet. 2018 May 11. pii: S0140-6736(18)30801.
    PubMed     Abstract available


  151. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
    Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
    Lancet. 2018 May 4. pii: S0140-6736(18)30664.
    PubMed     Abstract available


  152. DAMEN JAAG, Hooft L, Moons KGM
    Contemporary cardiovascular risk prediction.
    Lancet. 2018 May 4. pii: S0140-6736(18)30842.
    PubMed    


    April 2018
  153. DEHGHAN M, Mente A, Yusuf S
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply.
    Lancet. 2018;391:1681-1682.
    PubMed    


  154. HANSEL B, Roussel R, Giral P
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680.
    PubMed    


  155. KLEBER ME, Delgado GE, Dawczynski C, Lorkowski S, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1680-1681.
    PubMed    


  156. CAO XP, Tan CC, Yu JT
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679-1680.
    PubMed    


  157. CARBONE S, Billingsley H, Abbate A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1679.
    PubMed    


  158. LORKOWSKI S, Richter M, Linseisen J, Watzl B, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1678-1679.
    PubMed    


  159. ROSSOUW JE, Prentice RL
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677.
    PubMed    


  160. BHOPAL RS, Misra A
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1677-1678.
    PubMed    


  161. MANN J, Meerpohl J, Nishida C, McLean R, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    PubMed    


  162. REYNOLDS AN
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676.
    PubMed    


  163. KAHLEOVA H, Crosby L, Levin S, Barnard ND, et al
    Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
    Lancet. 2018;391:1676-1677.
    PubMed    


  164. CHU DK, Kim LH, Young PJ, Zamiri N, et al
    Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.
    Lancet. 2018;391:1693-1705.
    PubMed     Abstract available


    March 2018
  165. ALKHALIL M
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:936.
    PubMed    


  166. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
    Bioresorbable polymer drug-eluting stents - Authors' reply.
    Lancet. 2018;391:936-937.
    PubMed    


  167. SHAH R
    Bioresorbable polymer drug-eluting stents.
    Lancet. 2018;391:935-936.
    PubMed    


  168. MOTOVSKA Z, Bhatt DL
    12 months of DAPT after acute coronary syndrome still beats 6 months.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
    PubMed    


  169. HAHN JY, Song YB, Oh JH, Cho DK, et al
    6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
    PubMed     Abstract available


    February 2018
  170. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
    Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
    PubMed     Abstract available


  171. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    PubMed    


  172. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed    


  173. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed    


    January 2018
  174. JOBS A, Desch S, Thiele H
    Great expectations - Authors' reply.
    Lancet. 2018;391:306-307.
    PubMed    


  175. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
    Great expectations.
    Lancet. 2018;391:306.
    PubMed    


  176. ANAND SS, Bosch J, Eikelboom JW, Connolly SJ, et al
    Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2018;391:219-229.
    PubMed     Abstract available


  177. BOCHATON T, Ovize M
    Circadian rhythm and ischaemia-reperfusion injury.
    Lancet. 2018;391:8-9.
    PubMed    


  178. BROWN DL, Redberg RF
    Last nail in the coffin for PCI in stable angina?
    Lancet. 2018;391:3-4.
    PubMed    


  179. GERBER RT, Gershlick AH
    A SENIOR moment? Bare-metal stents in elderly patients.
    Lancet. 2018;391:4-6.
    PubMed    


    December 2017
  180. SCHUMACHER H, Mahfoud F, Bohm M
    Overestimation of cardiovascular outcome incidence - Authors' reply.
    Lancet. 2017;390:2547.
    PubMed    


  181. YE Y, Fonseca R
    Overestimation of cardiovascular outcome incidence.
    Lancet. 2017;390:2546-2547.
    PubMed    


  182. THURSTON GD, Newman JD
    Walking to a pathway for cardiovascular effects of air pollution.
    Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
    PubMed    


  183. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    PubMed     Abstract available


  184. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
    A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
    Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
    PubMed     Abstract available


    November 2017
  185. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
    Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
    PubMed     Abstract available


  186. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
    Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
    PubMed     Abstract available


  187. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
    Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
    Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
    PubMed     Abstract available


  188. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
    Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
    PubMed     Abstract available


    October 2017
  189. VARENNE O, Cook S, Sideris G, Kedev S, et al
    Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
    Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
    PubMed     Abstract available


  190. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
    Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
    Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
    PubMed     Abstract available


  191. BYRNE RA, Schuster T
    Biodegradable polymer drug-eluting stents: caveat emptor.
    Lancet. 2017;390:1814-1816.
    PubMed    


    September 2017
  192. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
    The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
    Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
    PubMed     Abstract available


    August 2017
  193. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    PubMed     Abstract available


  194. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
    Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
    PubMed     Abstract available


  195. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    PubMed     Abstract available


    April 2017
  196. SHAH R
    Optical coherence tomography-guided PCI.
    Lancet. 2017;389:1607.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: